Apriori Bio Announces Collaboration with the Francis Crick Institute
Apriori to leverage foundational insights from the Crick’s Legacy Study to further validate Octavia platform’s ability to predict viral evolution and vaccine performance Apriori Bio, a biotechnology company focused on developing variant-resilient vaccines, today announced a research collaboration with the Francis Crick Institute to better understand critical aspects of immune response, with the goal of informing…
